Company profile
Alto Neuroscience, Inc.
Pipeline7 assets
- ALTO-207CTC-501 / D3/D2 & 5-HT3 / fixed-dose combination of pramipexole and ondansetron / NeuropsychiatryTreatment-resistant depressionPhase 2bactive
- ALTO-300MT1/2 & 5HT2C / oral small molecule / NeuropsychiatryMajor depressive disorderPhase 2bactiveUnited States
- ALTO-100BDNF/neural plasticity / oral small molecule / NeuropsychiatryBipolar depressionPhase 2bactive
- ALTO-101PDE4 / transdermal PDE4 inhibitor / NeuropsychiatryCognitive impairment associated with schizophreniaPhase 2active
- ALTO-203Histamine H3 receptor / oral small molecule inverse agonist / NeuropsychiatryMajor depressive disorder with anhedoniaPhase 2aactive
- ALTO-202NMDA NR2B/GluN2B / oral small molecule negative allosteric modulator / NeuropsychiatryMajor depressive disorderactive
- ALTO-208CTC 413 / D3/D2 & NK-1 / fixed-dose combination of pramipexole and aprepitant / NeurologyParkinson's diseaseactive